Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Most anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLCs) are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However, patients with these cancers invariably relapse, typically within 1 year, because of the development of drug resistance. Herein,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Katayama, Ryohei, Shaw, Alice T., Khan, Tahsin M., Mino-Kenudson, Mari, Solomon, Benjamin J., Halmos, Balazs, Jessop, Nicholas A., Wain, John C., Yeo, Alan Tien, Benes, Cyril, Drew, Lisa, Saeh, Jamal Carlos, Crosby, Katherine, Sequist, Lecia V., Iafrate, A. John, Engelman, Jeffrey A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3385512/
https://ncbi.nlm.nih.gov/pubmed/22277784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3003316
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge